Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10

Eur Neurol. 2003;49(3):137-41. doi: 10.1159/000069082.

Abstract

We designed this longitudinal study to clarify the short- and long-term effects of mitoxantrone on the immune system in a subgroup of multiple sclerosis patients treated at our centre. After 14 days we found a highly significant sustained reduction of leucocytes, primarily affecting neutrophils and most lymphocyte subsets except for naive and activated T lymphocytes. The CD4/CD8 ratio and serum immmunoglobulin levels were not affected. Furthermore, whole blood-stimulated mononuclear cell IL-10 production showed a significant lower level 2 weeks treatment, whereas basal IL-10 as well as stimulated and basal TNF-alpha secretion showed no significant changes. Longitudinal data disclosed a persistent decrease of B lymphocytes, while secretion of immunoglobulins, IL-10, and TNF-alpha was not altered in the follow-up. In conclusion, we confirmed a selective short-term effect of mitoxantrone therapy on most lymphocyte subpopulations, but not on immunoglobulines or the pro- and anti-inflammatory cytokines TNF-alpha and IL-10, which do not serve as possible response markers.

MeSH terms

  • Adult
  • Cytokines / biosynthesis*
  • Disability Evaluation
  • Female
  • Humans
  • Immunoglobulins / biosynthesis*
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-10 / biosynthesis
  • Leukocyte Count
  • Longitudinal Studies
  • Lymphocyte Subsets / pathology*
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / pathology*
  • Multiple Sclerosis / physiopathology
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Cytokines
  • Immunoglobulins
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Mitoxantrone